Minnesota Oncology Hematology

The trials here

What the 13 trials at this site are about, from their registry records.

Conditions

• Childhood cancers4 trials
• Ovarian cancer3 trials
• Sarcoma3 trials
• Lung cancer2 trials
• Cervical cancer1 trial
• Endometrial cancer1 trial
• Kidney cancer1 trial
• Multiple myeloma1 trial
• Prostate cancer1 trial

Phase

• Phase 25 trials
• Phase 35 trials
• Phase 12 trials

Status

• Completed6 trials
• Recruiting4 trials
• Active, not recruiting2 trials
• Terminated1 trial

Lead sponsor

• Hoffmann-La Roche3 trials
• USWM CT, LLC2 trials
• Aadi Bioscience, Inc.1 trial
• CanariaBio Inc.1 trial
• GOG Foundation1 trial
• and 5 more

Running trials

• Recruiting

  A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

  NCT06072781· Phase 3· Verastem, Inc.· Source

  Contact: Kayla McDonald

• Recruiting

  Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

  NCT05972135· Phase 2· SCRI Development Innovations, LLC· Source

  Contact: Sarah Cannon Development Innovations, LLC

• Recruiting

  Study of ORIC-944 in Patients With Metastatic Prostate Cancer

  NCT05413421· Phase 1· ORIC Pharmaceuticals· Source

  Contact: ORIC Clinical

• Recruiting

  A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

  NCT04831580· GOG Foundation· Source

  Contact: Jessica Thomes-Pepin

• Active, not recruiting

  Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

  NCT04498117· Phase 3· CanariaBio Inc.· Source

• Active, not recruiting

  Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

  NCT03967223· Phase 2· USWM CT, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Cervical cancer1 recruiting
• Multiple myeloma1 recruiting
• Ovarian cancer1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Completed

  Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

  NCT05103358· Phase 2· Aadi Bioscience, Inc.· Source

• Completed

  A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

  NCT04513925· Phase 3· Hoffmann-La Roche· Source

• Terminated

  A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment

  NCT04338269· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

  NCT04256421· Phase 3· Hoffmann-La Roche· Source

• Completed

  Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

  NCT05993299· Phase 2· USWM, LLC (dba US WorldMeds)· Source

• Completed

  Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

  NCT06703346· Phase 2· USWM CT, LLC· Source

• Completed

  Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

  NCT03748186· Phase 1· Sutro Biopharma, Inc.· Source